AcuamarkDX

Coming – December 3

NYC Lunch And Learn with CEO Bernard Peperstraete

Date and Time

December 3

12:00 PM ET

Details will be provided upon RSVP approval

About this Event

Please join us in midtown Manhattan for an exclusive luncheon with Acuamark Diagnostics, a biotech innovator that has developed a breakthrough blood test that identifies cancers at their earliest, most treatable stages.

Unlike current invasive cancer-specific screening methods, AcuamarkDX’s assay uses optimized quantitative PCR and AI to detect markers across multiple cancer types through a single blood draw integrated into routine checkups. Clinical validation shows up to 97% detection accuracy for Stage 1–2 colorectal cancers while reducing false positives versus stool or imaging tests.

Register today to meet with Bernard Peperstraete, CEO of AcuamarkDX, in New York City to hear more about the company’s programs, and why they were awarded  “The Most Promising 2025 Life Science Company” at the 2025 Texas Life Science Forum.

Sign Up Today

SHARE THIS EVENT

This presentation contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts and referenced statistics, contained in this presentation, including statements regarding future company strategy, operations, financial position, revenues, projected costs, plans and objectives of management, will be forward-looking statements.

All statements and expressions are the sole opinion of the company and are subject to change without notice. The Company is not liable for any investment decisions by its readers or subscribers. It is strongly recommended that any purchase or sale decision be discussed with a financial advisor, or a broker-dealer, or a member of any financial regulatory bodies. The information contained herein has been provided as an information service only. The accuracy or completeness of the information is not warranted and is only as reliable as the sources from which it was obtained. Investors are cautioned that they may lose all or a portion of their investment in this or any other company. Information contained herein contains “forward looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities and Exchange Act of 1934, as amended. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical facts and may be “forward looking statements”. Forward looking statements are based on expectations, estimates and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of words such as “expects”, “will”, “anticipates”, “estimates”, “believes”, or by statements indicating certain actions “may”, “could”, “should” or “might” occur.